Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 31,379 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 31,379 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total value of $986,555.76. Following the transaction, the chief executive officer owned 738,809 shares in the company, valued at $23,228,154.96. This trade represents a 4.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Twist Bioscience Stock Down 4.0%

Shares of TWST traded down $1.32 during mid-day trading on Monday, reaching $31.57. The company had a trading volume of 1,224,978 shares, compared to its average volume of 1,305,728. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The firm has a 50-day moving average price of $28.97 and a 200 day moving average price of $31.82. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -21.77 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. On average, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after purchasing an additional 302 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Twist Bioscience in the 2nd quarter worth about $97,000. CWM LLC raised its position in Twist Bioscience by 61.4% in the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after purchasing an additional 1,648 shares during the period. Finally, Bayforest Capital Ltd raised its position in Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock worth $191,000 after purchasing an additional 1,604 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Evercore ISI decreased their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Finally, Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Nine analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $48.56.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.